Sophie J. Bakri, M.D.

The purpose of this study is to develop a Registry of participants with MacTel Type 2 (as confirmed by the Reading Center) who may agree to be contacted for inclusion in future clinical trials. The Registry participants include new participants and participants from the NHO, Genetic I and Genetics II studies who agree to continue to participate. 

The second objective is to continue to identify whether there is a genetic link associated with MacTel Type 2. All participants who have not previously provided a blood sample will be given the option to provide a blood sample for genetic sequencing.

The purpose of this study is to learn about cell function in different tissues of the eye in various ocular diseases via transcriptomics in the Mayo Clinic laboratory.

The purose of this study is to determine the safety and effectiveness of treating macular tetangiectasia type 2 patients with Renexus.

The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of APL-2 in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).

The primary objective of this study is to evaluate mean change in best-corrected visual acuity (BCVA) of RGX-314 relative to ranibizumab at Week 38.

Second objectives of this study are to evaluate the safety and tolerability of RGX-314 through Week 102, to evaluate the effect of RGX-314 relative to ranibizumab on BCVA, to evaluate the effect of RGX-314 relative to ranibizumab on central retinal thickness (CRT) as measured by spectral domain-ocular coherence tomography (SD-OCT), to evaluate the effect of RGX-314 relative to ranibizumab on center point thickness (CPT) as measured by SD-OCT, to assess the need for supplemental anti-vascular endothelial growth factor (VEGF) therapy in the RGX-314 treatment arms, to assess aqueous protein concentrations of RGX-314, and to evaluate the immunogenicity of RGX-314.

The purpose for this follow-up study is to learn about the long term effects of treatment for Neovascular Age-related Macular Degeneration on vision and eye health among people who are treated over a 5 to 6 year period. 

The purpose of this study is to review the management and outcomes of patients who had vitreoretinal surgery at the Mayo Clinic. A search will be made using relevant ICD-9 codes and surgical databases. Presenting symptoms, visual acuity, management strategies, visual and anatomic outcomes will be reviewed.

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for 12 months. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.